Predictors of Adherence to Orencia

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01136707

IM101-266

Details and patient eligibility

About

The purpose of this study is to examine the relationship between loading dose and adherence to Orencia.

Enrollment: 422 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients will be identified based on the presence of first infusion claim during study period for Orencia
• At least 1 medical or facility claim for rheumatoid arthritis at the time of or 6 months prior to index date
• Patients are required to be continuously enrolled for a minimum pre-index and follow-up period as detailed below
• Patients with a minimum of 3 infusion claims for Orencia
• Only those patients will be included whose first 3 infusion claims occur within 84 days

Exclusion criteria

• Patients less than 18 years of age at index date.
• One or more diagnoses of regional enteritis (including Crohn's disease), ulcerative colitis, anal or intestinal fistula, ankylosing spondylitis or other inflammatory spondylopathy, psoriatic arthropathy, or psoriasis any time during the 6-month pre-index period
• Patients who switch between biologics within their first three infusion claims
• Restarts, defined as those patients who go back on Orencia after a gap of 42 days
• Patients who are on other biologics at the same time as Orencia

Trial design

422 participants in 1 patient group

Patients with rheumatoid arthritis new to Orencia